Head of TA Non-Onco,ExpMED China

About Innovation Unit China Innovation Unit China (China R&D Center) is a strategic innovation hub within Boehringer Ingelheim’s global R&D network, established to harness China’s rapidly evolving scientific capabilities and vibrant innovation ecosystem. By integrating Experimental Medicine, External Innovation, Development CMC, and Clinical Pharmacology & Non-clinical Safety Science, IU China connects promising science with early development expertise to accelerate high-potential opportunities, contribute to the global pipeline, and help accelerate breakthrough therapies for patients in China and around the world. Responsibilities - TA Strategy & Portfolio Contribution(INFL, CRM, EH&MH)

1. 01

   Define and execute the ExpMED China strategy for the non-ONC TAs, aligned with the global ExpMED TA strategies, the ExpMED China / IU strategy and portfolio priorities (Simplify – Focus – Accelerate).

2. 02

   Ensure China participation in global CS-to-PoC programs of the non-ONC TAs (default model: join global programs with China focus to accelerate enrollment speed and decision quality); for selected non-ONC assets (e.g., INFL, advanced modalities), shape China-led / China-first components from protocol design and dose escalation onward.

3. 03

   Bring the China perspective (medical practice, patient populations, regulatory

, competitive landscape) into global non-ONC early clinical development plans and governance; propose China-enabled acceleration options per asset. 4)Prioritize resources across TAs and programs according to portfolio value and ExpMED China priorities. -Scientific & Clinical Leadership

1. 01

   Provide medical-scientific leadership for the design, conduct and interpretation of non-ONC CS-to-PoC studies with China participation; ensure scientific rigor, patient safety and compliance with ICH-GCP and NMPA/CDE requirements.

2. 02

   Review and approve China-relevant protocols and amendments, study documents, clinical sections of regulatory submissions, data interpretations and publications within delegated authority.

3. 03

   Enable timely, high-quality PoC and governance decisions for China-supported non-ONC programs within global governance frameworks.

4. 04

   Maintain deep knowledge of emerging science, standard of care and competitor activity in China across INFL, CRM and EH&MH. -China Evidence Generation & Translational Science

5. 01

   Ensure generation of China-specific clinical, translational and biomarker evidence in the non-ONC TAs that supports global development, China regulatory (NMPA/CDE) and value strategies.

6. 02

   Partner with Clinical Pharmacology & Non-clinical Safety Sciences (CPS), Translational Medicine / Biomarker and Data & Analysis functions to integrate China data (e.g., PK/PD, ethnic sensitivity, biomarkers) into global programs; ensure compliant handling of human genetic resources and data. -Clinical Network, External Engagement & BD&L Support

7. 01

   Build and sustain a dedicated network of early clinical investigators, Phase I units and specialty sites with INFL, CRM and EH&MH expertise across China; together with Clinical Operations, establish efficient early clinical development processes with these partners.

8. 02

   Represent ExpMED China externally to key opinion leaders, academic institutions, biotech partners and CROs in the non-ONC TAs; support health authority interactions together with Regulatory Affairs.

9. 03

   Provide ExpMED clinical assessment of China-sourced non-ONC external innovation and licensing opportunities in support of the External Innovation / BD&L strategy of the China R&D Center. -Team & Talent Leadership

10. 01

    Build, lead and retain a high-performing non-ONC TA team within ExpMED China [team size and direct/matrix reporting of e.g. Clinical Development Experts, Clinical Trial Execution Experts, Safety Physicians, Biomarker Experts and Statisticians to be confirmed per final ExpMED China structure], including colleagues holding global roles in programs of strategic relevance; set clear objectives and ensure delivery.

11. 02

    Develop talent and succession for the non-ONC TAs in China and support cross-border mobility and capability exchange with global ExpMED.

12. 03

    Foster an inclusive, high-accountability culture of open communication, compliance, scientific excellence and the experimental mindset, aligned with Our Behaviors. -Matrix & Cross-Functional Collaboration

13. 01

    Act as the primary China counterpart of the global ExpMED TA Heads for INFL, CRM and EH&MH and their teams; ensure one-voice alignment between global TA strategy and China execution.

14. 02

    Partner with the ExpMED China Clinical Operations, Data & Analysis and Quality / Biomarker / Regulatory Support functions; with CPS, Development CMC and External Innovation within the China R&D Center; with Safety Science / Pharmacovigilance, Regulatory Affairs China, Biostatistics and the Development TA teams; and with the China Human Pharma Business Unit / Medical Affairs.

15. 03

    Participate in and contribute to relevant global and local governance forums within defined decision thresholds. -Governance, Compliance & Quality

16. 01

    Ensure full compliance with global SOPs, GxP / ICH-GCP, quality standards and ethical requirements, while adapting execution to Chinese regulatory realities (NMPA/CDE, Human Genetic Resources regulations, data protection, ethics committees).

17. 02

    Proactively identify, manage and escalate scientific, operational and compliance risks in non-ONC China programs. Qualifications Experience: • ≥10 years of combined experience across hospital, academic and industry settings in clinical development, with significant experience in Experimental Medicine / early clinical development and a track record of driving programs to PoC. • Leadership experience in complex, matrixed R&D environments, including leading teams of clinical scientists / physicians. • Demonstrated experience working in or with China-based R&D and clinical ecosystems, including an established network with investigators and Phase I / specialty sites; experience in more than one non-Oncology TA is a plus. Skills & competencies: • Scientific expertise: deep understanding of disease biology, early clinical trial design and translational medicine. • Strategic thinking: ability to translate global strategy into China execution plans and to prioritize across TAs. • Leadership: inspires and develops multidisciplinary teams; builds capability and succession. • Communication and influence: excellent ability to engage and influence senior internal and external stakeholders across cultures; business fluency in English and Mandarin Chinese. • Regulatory knowledge: working knowledge of ICH-GCP, NMPA/CDE requirements, China Human Genetic Resources regulations and global drug development. • Compliance and risk mindset: strong local compliance culture; proactive risk identification and escalation. • Innovation and agility: track record of implementing novel approaches in early clinical development; thrives in a fast-paced, ambiguous environment.